Difficult-to-treat basal cell cancer: therapeutic possibilities in the era of targeted therapies
Absztrakt
Basal cell carcinoma is a common skin cancer with various risk factors. Treatment options include surgery, chemotherapy, and targeted therapy. HH pathway inhibitors have become integral in managing difficult-to-treat BCC. Sonidegib is a safe and effective drug with mild to moderate side effects, and immune checkpoint inhibitors are an alternative treatment for advanced BCC patients.
Leírás
Kulcsszavak
basal cell carcinoma, immunotherapy, sonidegib, vismodegib, hedgehog pathway inhibitors, targeted therapy